Bellevue Life Sciences Faces Delisting Notice

TL;DR

BLAC got a delisting warning, might be off the exchange soon.

AI Summary

Bellevue Life Sciences Acquisition Corp. filed an 8-K on August 22, 2024, reporting a notice of delisting or failure to meet continued listing standards as of August 20, 2024. The company, incorporated in Delaware, is involved in the surgical and medical instruments sector.

Why It Matters

This filing indicates potential delisting from an exchange, which could significantly impact the liquidity and trading of the company's securities.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued public trading and investor confidence.

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Registrant
• August 20, 2024 (date) — Date of earliest event reported
• August 22, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma

Filing Documents

• d227622d8k.htm (8-K) — 33KB
• 0001193125-24-205378.txt ( ) — 212KB
• blacu-20240820.xsd (EX-101.SCH) — 5KB
• blacu-20240820_def.xml (EX-101.DEF) — 15KB
• blacu-20240820_lab.xml (EX-101.LAB) — 26KB
• blacu-20240820_pre.xml (EX-101.PRE) — 16KB
• d227622d8k_htm.xml (XML) — 9KB

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the Company's plans with respect to its interactions with Nasdaq. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. They involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by these statements. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Current Report on Form 8-K, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Actual results and stockholders' value will be affected by a variety of risks and factors, including, without limitation, international, national and local economic conditions, merger, acquisition and business combination risks, financing risks, geo-political risks, acts of terror or war, and those risk factors described under "Item 1A. Risk Factors" of the Company's Annual Report on Form 10-K filed with the SEC on April 17, 2024, in the section titled "Risk Factors" contained in our prospectus dated February 9, 2023, and in other reports the Company files with the SEC. Many of the risks and factors that will determine these results and stockholders' value are beyond the Company's ability to control or predict. All such forward-looking statements speak only as of the date of this Current Report on Form 8-K. The Compa

View Full Filing

View this 8-K filing on SEC EDGAR